<DOC>
	<DOCNO>NCT00006237</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . It yet know whether interferon alfa effective without combination chemotherapy interleukin-2 melanoma . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa without combination chemotherapy consist cisplatin , vinblastine , dacarbazine , plus interleukin-2 , treat patient melanoma .</brief_summary>
	<brief_title>S0008 : Chemotherapy Plus Biological Therapy Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival disease-free survival patient high-risk melanoma treat interferon alfa v cisplatin , vinblastine , dacarbazine plus interferon alfa interleukin-2 . - Compare toxic effect treatment regimens patient . - Determine relationship minimal residual disease ( MRD ) status 12 week 52 week overall survival patient treat regimen . - Compare effect treatment regimens MRD status patient . - Determine relationship clinical characteristic ( number involve lymph node , ulcerated primary , extracapsular extension ) MRD patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord nodal status ( N1 N2 v N3 ) , degree lymph node involvement ( micrometastases vs macrometastases , include satellite/in-transit metastasis ) , ulceration primary tumor ( yes v v unknown primary ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive interferon alfa IV day 1-5 week 1-4 follow interferon alfa subcutaneously ( SC ) day 1 , 3 , 5 week 5-52 absence disease progression unacceptable toxicity . - Arm II : Patients receive cisplatin IV 30 minute follow vinblastine IV day 1-4 . Patients also receive dacarbazine IV 1 hour day 1 , interleukin-2 IV 96 hour day 1-4 , interferon alfa SC day 1-5 , 8 , 10 , 12 . In addition , patient receive filgrastim ( G-CSF ) SC day 6-15 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 410 patient ( 205 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven melanoma cutaneous origin unknown primary initial presentation primary first clinically detect nodal satellite/intransit recurrence No distant metastases No melanoma ocular , mucosal , noncutaneous origin One follow criterion must apply patient newly diagnose melanoma OR previously diagnose primary current subsequent , clinical , regional nodal disease and/or satellite/intransit disease : Ulcerated primary melanoma 1 involve lymph node ( micro/occult macro/clinically overt ) Nonulcerated unknown primary melanoma one macro/clinically overt lymph node metastasis , include single mat nodal mass No nonulcerated unknown primary tumor single micrometastatic lymph node Nonulcerated melanoma two lymph node metastasis ( micro/occult macro/clinically overt ) and/or mat node Any satellite/in transit metastasis without lymph node involvement Patients recurrent disease must recurrent disease regional nodal basin prior complete lymphadenectomy Multiple regional nodal basin involvement allow appropriate anatomic drainage basin primary site Patients must disease free time enrollment base follow surgical criterion : Patients initial presentation melanoma must undergo adequate wide excision primary lesion Patients previously diagnose melanoma must disease resect pathologically negative margin disease primary site second resection primary Full lymphadenectomy require patient include positive sentinel node positive satellite/intransit metastasis No 56 day since prior lymphadenectomy OR surgery remove recurrent disease prior complete lymphadenectomy Must willing participate minimal residual disease study register study 3/1/2003 later PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN LDH alkaline phosphatase great 2 time ULN ( normal value require contrastenhanced CT scan MRI liver ) No know recent hepatitis positivity PCR Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 75 mL/min Cardiovascular : No congestive heart failure No coronary artery disease No serious cardiac arrhythmia No prior myocardial infarction Normal cardiac stress test require following present : Over age 50 Abnormal EKG History cardiac disease Pulmonary : No symptomatic pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No autoimmune disorder condition immunosuppression No prior malignancy within past 5 year except follow : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer remission HIV negative No known AIDS HIV1 associate complex PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy , include interferon , interleukin , levamisole , biologic response modifier No concurrent biologic therapy Chemotherapy : No prior chemotherapy ( include infusion perfusion therapy ) No concurrent chemotherapy Endocrine therapy : No concurrent systemic corticosteroid topical steroid cream Concurrent steroid antihistamine allow alternative No concurrent hormonal therapy Radiotherapy : No prior radiotherapy Prior postlumpectomy radiotherapy breast cancer allow No concurrent radiotherapy Surgery : See Disease Characteristics No concurrent surgery Other : No concurrent antihypertensive medication ( arm II ) No concurrent immunosuppressive agent No concurrent anticancer therapy Antihistamines allow alternative medication suitable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>